drug · small molecule
crofelemer DR
Marketedupdated 3mo agoby Napo Pharmaceuticals Inc🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for diarrhea and 2 investigational indications.
targets
Anoctamin-1Cystic fibrosis transmembrane conductance regulator
all catalysts(0)
nothing on the calendar yet
Trials studying crofelemer DR
- phase3Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)
- EP1Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
- phase4Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients
- phase2Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
- phase2Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)
- phase3Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 31, 2031
~5.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Oct 31, 2031method-of-use (U-1319)US 8962680
- Oct 31, 2031method-of-use (U-1319)US 9585868
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 57m ago
Found something off?
comments(0)
5-min edit window · permanent after that